-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the features of the iHuPBMC-NK platform?
Author:
InnoModels
Release time:
2024-03-25
Among the many components of the immune system, natural killer (NK) cells have attracted much attention for their unique non-specific killing ability and rapid response mechanism. The iHuPBMC-NK platform launched by InnoModels Biotechnology is designed for in-depth study of the functions and applications of NK cells. The platform integrates a number of advanced technologies with distinctive features and plays an important role in NK cell research.
1、Highly simulates the human environment
The iHuPBMC-NK platform adopts a humanized peripheral blood single nucleated cell (PBMC) system, which contains not only NK cells, but also a rich variety of other immune cell types, which greatly improves the physiological relevance and accuracy of the experiments. By simulating the complex microenvironment in the human body, the platform can more realistically reflect the behavior and function of NK cells in vivo.
2. Precise regulation of NK cell activity
The platform has the ability to precisely regulate the activity of NK cells. Researchers can regulate the proliferation, differentiation and activation process of NK cells according to experimental needs, so as to deeply explore the mechanism of NK cells in different physiological and pathological conditions.
3、Promote the development of NK cell therapy
With the rise of immunotherapy, NK cell therapy shows great potential in the fields of cancer, viral infection, etc. The iHuPBMC-NK platform provides strong support for the research of NK cell therapy. Through this platform, researchers can assess the impact of different treatment strategies on NK cell function, optimize treatment plans, and promote NK cell therapy from laboratory to clinical application.

4. Powerful data analysis and processing capabilities
The platform is equipped with an advanced data analysis and processing system, which enables comprehensive and in-depth analysis of multiple biological features of NK cells. Through high-throughput sequencing, single-cell sequencing and other technical means, researchers can obtain key information on gene expression, protein interactions, etc. of NK cells, which provides strong support for revealing the complexity of NK cell functions.
5. Easy to operate and reproducible
The iHuPBMC-NK platform is designed to focus on user-friendliness and reproducibility, with easy and fast experimental operation and stable and reliable results. This helps researchers to carry out NK cell-related research quickly and efficiently in busy laboratory work.
In summary, the iHuPBMC-NK platform of InnoModels Biotechnology has become a powerful assistant in the field of NK cell research with its highly simulated human environment, precise regulation of NK cell activity, promotion of NK cell therapy, powerful data analysis and processing capabilities, as well as ease of operation and reproducibility. With the continuous revelation of NK cell function and the advancement of immunotherapy technology, the platform is expected to play an even more important role in the future and make significant contributions to human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd